Apellis Pharmaceuticals, Inc.
APLS
Apellis Pharmaceuticals, Inc., a commercial-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of therapeutic compounds through the inhibition of the complement system for autoimmune and inflammatory diseases. The company's lead product candidate is pegcetacoplan that is in Phase III clinical trials for the treatment of geographic atrophy (GA) in age-relaā¦ read more
Healthcare
Biotechnology
8 years
USD
Exclusive to Premium users
Price
per share adjusted in USD$19.63
Price-1.80%
-$0.36
1Y
Price
Market Cap
$2.509b
Mid
Price/Earnings 3y Avg5y Avg
109.1x
Premium
Premium
Financial Reports
Key metrics over the past few years and other important metrics. Amounts in USD.-23.7%
EBITDA Margin-29.5%
Net Profit Margin-7.0%
Free Cash Flow Margin-23.7%
EBITDA Margin-29.5%
Net Profit Margin-7.0%
Free Cash Flow MarginRevenue
$1.004b
+28.5%
1y CAGR+183.8%
3y CAGR+141.2%
5y CAGREarnings
$22.388m
+111.3%
1y CAGR+64.3%
3y CAGR+51.4%
5y CAGREPS
$0.18
+110.6%
1y CAGR+67.4%
3y CAGR+58.2%
5y CAGRBook Value
$370.147m
$1.075b
Assets$705.110m
Liabilities$486.307m
DebtDebt to Assets
45.2%
6.9x
Debt to EBITDAFree Cash Flow
$45.014m
+151.4%
1y CAGR+73.7%
3y CAGR+57.4%
5y CAGRNo items found.
Press Releases
Statements and updates from the company